Issue link: https://www.e-digitaleditions.com/i/1521797
Inhalation June 2024 29 15. Gavini, E. et al. Nasal administration of Carba- mazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm 307, 9-15 (2006). 16. Jug, M., et al. Development of a cyclodex- trin-based nasal delivery system for Lorazepam. Drug Dev Ind Pharm 34, 817-826 (2008). 17. Kulkarni, A. D., et al. In vitro, ex vivo and in vivo performance of chitosan-based spray-dried nasal mucoadhesive microspheres of diltiazem hydrochlo- ride. J Drug Deliv Sci Technol 31, 108-117 (2016). 18. Abdel M., et al. Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. Eur J Pharm Sci 51, 59-66 (2014). 19. Huh, Y., et al. Preparation and evaluation of spray-dried hyaluronic acid microspheres for intra- nasal delivery of fexofenadine hydrochloride. Eur J Pharm Sci 40, 9-15 (2010). 20. Tiozzo Fasiolo, L., et al. Anti-inflammatory flur- biprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. J Drug Target 27, 984-994 (2019). 21. Cho, W., et al. Design of salmon calcitonin par- ticles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. Int J Pharm 478, 288-296 (2015). 22. Garmise, R. J., et al. Novel dry powder prepara- tions of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 8, 2-10 (2007). References 1. Fortuna, A., et al. Intranasal delivery of systemic- acting drugs: Small-molecules and biomacromole- cules. Eur Journal Pharm Biopharm 88, 8-27 (2014). 2. Hussein, N. R., et al. Advances in nasal drug deliv- ery systems, in Advances in Medical and Surgical Engineering 279-311 (Elsevier, 2020). doi:10.1016/ b978-0-12-819712-7.00015-2. 3. Pires, A., et al. Intranasal drug delivery: How, why and what for? J Pharm Sci 12, 288–311 (2009). 4. Khan, A. R., et al. Progress in brain targeting drug delivery system by nasal route. JCR 268, 364-389 (2017). 5. He, Y., et al. Amorphous solid dispersions: Utili- zation and challenges in drug discovery and develop- ment. J Pharm Sci 104, 3237-3258 (2015). 6. Tiozzo Fasiolo, L., et al. Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. Int J Pharm 605, 120827 (2021). 7. Vig, B., et al. Formulation, process development, and scale-up: Spray-drying amorphous solid disper- sions for insoluble drugs, in Developing Solid Oral Dosage Forms 793-820 (Academic Press, 2017). doi:10.1016/B978-0-12-802447-8.00030-3. 8. Marttin, E., et al. Nasal absorption of dihydro- ergotamine from liquid and powder formulations in rabbits. J Pharm Sci 86, 802-807 (1997). 9. Illum, L., et al. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm 222, 109-119 (2001). 10. Pringels, E., et al. Influence of deposition and spray pattern of nasal powders on insulin bioavail- ability. Int J Pharm 310, 1-7 (2006). 11. Cho, H.-J., et al. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron–cyclodextrin complex and carboxymeth- ylcellulose for intranasal delivery. Int J Pharm 400, 59-65 (2010). 12. Pozzoli, M., et al. Development of a Soluplus budesonide freeze-dried powder for nasal drug deliv- ery. Drug Dev Ind Pharm 43, 1510-1518 (2017). 13. Fallacara, A., et al. In vitro characterization of physico-chemical properties, cytotoxicity, bioactiv- ity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. Int J Pharm 558, 341-350 (2019). 14. Gavini, E., et al. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclo- pramide: In-vitro/ex-vivo studies. JPP 57, 287-294 (2005).